This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Osteoporosis  • Statistics and Research Methods  • Neurology  • Alzheimer Disease  • Randomized Controlled Trial  • Stroke  • Alert me on articles by topic

Jutta Martha Halbekath; Stefanie Schenk; Andreas von Maxen, MD; Gabriele Meyer, PhD; Ingrid Mühlhauser, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

With concern, we read the trials conducted by Sato and colleagues comparing risedronate sodium with placebo in male patients with stroke¹ and female patients with Alzheimer disease (AD).²

Both trials were conducted in a single center. Yet, patients (500 women with AD and 280 men with stroke) were recruited in only 3 months: the patients with AD in March and April 2003 and the patients with stroke in April and May 2003. Related to a third single-center trial with risedronate in 374 female patients with stroke at the same hospital that was published by the group in 2005,³ a correspondence letter⁴ expressed concern about the high frequency of recruitment, which was performed in only 4 months (between April and July 2003).³ In their reply, Sato and colleagues⁵ stated that their hospital is a specialized center . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Risedronate for the Prevention of Hip Fractures: Concern About Validity of Trials—Reply
Yoshihiro Sato
Arch Intern Med. 2007;167(5):514-515.
EXTRACT | FULL TEXT